Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Non-randomized Controlled, Single-arm, Phase II Clinical Trial of Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

NCT04995016 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.

NCT NCT04995016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04995016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Non-randomized Controlled, Single-arm, Phase II Clinical Trial of Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
Lead sponsor
Tianjin Medical University Second Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 20, 2021
Completion date
August 20, 2023
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, renal cell carcinoma